Edward P. K. Parker

Edward P. K. Parker

Auto-generated profile, based on publicly available information

Edward P. K. Parker

London School of Hygiene & Tropical Medicine

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2017 in Future Microbiology
Verified
Journal Article
Open access
EPEdward P K Parker
Edward P K Parker
SRSasirekha Ramani
Sasirekha Ramani
BLBenjamin A Lopman
Benjamin A Lopman
JCJames A Church
James A Church
MIMiren Iturriza-Gomara
Miren Iturriza-Gomara
NGNicholas C Grassly
Nicholas C Grassly
Oral vaccines are less immunogenic when given to infants in low-income compared with high-income countries, limiting their potential public health impact. Here, we review factors that might contrib...

1 October 2015 in Current Opinion in Infectious Diseases
Verified
Journal Article
Open access
MPMargarita Pons-Salort
Margarita Pons-Salort
EPEdward P.K. Parker
Edward P.K. Parker
NGNicholas C. Grassly
Nicholas C. Grassly
Purpose of review There are over 100 serotypes of human enteroviruses, which cause a spectrum of illnesses, including meningitis, encephalitis, paralysis, myocarditis and rash. Increasing incidence of hand-foot-and-mouth disease in the Asia-Pacific region and recent outbreaks of enterovirus-associated disease, such as severe respiratory illness in the United States in 2014, highlight the threat of these viruses to human health. Recent findings We describe recent outbreaks of human enteroviruses and summarize knowledge gaps regarding their burden, spectrum of diseases and epidemiology. Summary Reported outbreaks of respiratory, neurological, skin and eye diseases associated with human enteroviruses have increased in frequency and size in recent years. Improved molecular diagnostics and genetic sequence analysis are beginning to reveal the complex dynamics of individual serotypes and genotypes, and their contribution to these outbreaks. However, the biological mechanisms underlying their emergence and transmission dynamics remain elusive. They are likely to involve changes in the virus, such as fitness, antigenicity, virulence or tropism, and in the human population, such as levels of sanitation and of homotypic and heterotypic immunity. Improvements in surveillance, serological surveys and detailed genetic and antigenic characterization of viral populations would help to elucidate these mechanisms. This will be important for the design of outbreak control and vaccine development strategies.

1 May 2021 in The Lancet Global Health
Verified
Journal Article
Open access
MSMadhumita Shrotri
Madhumita Shrotri
TSTui Swinnen
Tui Swinnen
BKBeate Kampmann
Beate Kampmann
EPEdward P K Parker
Edward P K Parker

1 January 2018 in Vaccine
Verified
Journal Article
Open access
EPEdward P.K. Parker
Edward P.K. Parker
IPIra Praharaj
Ira Praharaj
AZAnna Zekavati
Anna Zekavati
RLRobin P. Lazarus
Robin P. Lazarus
SGSidhartha Giri
Sidhartha Giri
NGNicholas C. Grassly
Nicholas C. Grassly
Oral rotavirus vaccines have consistently proven to be less immunogenic among infants in developing countries. Discrepancies in the intestinal microbiota, including a greater burden of enteropathogens and an altered commensal community composition, may contribute to this trend by inhibiting the replication of vaccine viruses. To test this possibility, we performed a nested case-control study in Vellore, India, in which we compared the intestinal microbiota of infants who responded serologically or not after two doses of Rotarix delivered at 6 and 10 weeks of age as part of a clinical trial (CTRI/2012/05/002677). The prevalence of 40 bacterial, viral, and eukaryotic pathogen targets was assessed in pre-vaccination stool samples from 325 infants using singleplex real-time PCR on a Taqman array card (TAC). In a subset of 170 infants, we assessed bacterial microbiota composition by sequencing the 16S rRNA gene V4 region. Contrary to expectations, responders were more likely than non-responders to harbor ≥1 bacterial enteropathogen at dose 1 (26% [40/156] vs 13% [21/157] of infants with TAC results who completed the study per protocol; χ2, P = .006), although this was not apparent at dose 2 (24% [38/158] vs 23% [36/158]; P = .790). Rotavirus shedding after dose 1 was negatively correlated with the replication of co-administered oral poliovirus vaccine (OPV). We observed no consistent differences in composition or diversity of the 16S bacterial microbiota according to serological response, although rotavirus shedding was associated with slightly more bacterial taxa pre-vaccination. Overall, our findings demonstrate an inhibitory effect of co-administered OPV on the first dose of Rotarix, consistent with previous studies, but in the context of OPV co-administration we did not find a strong association between other components of the intestinal microbiota at the time of vaccination and Rotarix immunogenicity.

15 February 2022 in The Lancet Global Health
Verified
Journal Article
Open access
EPEdward P K Parker
Edward P K Parker
SDShalini Desai
Shalini Desai
MMMelanie Marti
Melanie Marti
HNHanna Nohynek
Hanna Nohynek
DKDavid C Kaslow
David C Kaslow
AWAnnelies Wilder-Smith
Annelies Wilder-Smith

27 March 2023 in Vaccine
Verified
Journal Article
Open access
ACAgustin Ciapponi
Agustin Ciapponi
MBMabel Berrueta
Mabel Berrueta
EPEdward P.K. Parker
Edward P.K. Parker
Ariel BardachAriel Bardach
Ariel Bardach
AMAgustina Mazzoni
Agustina Mazzoni
PBPierre Buekens
Pierre Buekens
Assessment of COVID-19 vaccines safety during pregnancy is urgently needed. We conducted a systematic review and meta-analysis to evaluate the safety of COVID-19 vaccines, including their components and technological platforms used in other vaccines during pregnancy and animal studies to complement direct evidence. We searched literature databases from its inception to September 2021 without language restriction, COVID-19 vaccine websites, and reference lists of other systematic reviews and the included studies. Pairs of reviewers independently selected, data extracted, and assessed the risk of bias of the studies. Discrepancies were resolved by consensus. (PROSPERO CRD42021234185). We retrieved 8,837 records from the literature search; 71 studies were included, involving 17,719,495 pregnant persons and 389 pregnant animals. Most studies (94%) were conducted in high-income countries, were cohort studies (51%), and 15% were classified as high risk of bias. We identified nine COVID-19 vaccine studies, seven involving 309,164 pregnant persons, mostly exposed to mRNA vaccines. Among non-COVID-19 vaccines, the most frequent exposures were AS03 and aluminum-based adjuvants. A meta-analysis of studies that adjusted for potential confounders showed no association with adverse outcomes, regardless of the vaccine or the trimester of vaccination. Neither the reported rates of adverse pregnancy outcomes nor reactogenicity exceeded expected background rates, which was the case for ASO3- or aluminum-adjuvanted non-COVID-19 vaccines in the proportion meta-analyses of uncontrolled studies/arms. The only exception was postpartum hemorrhage after COVID-19 vaccination (10.40%; 95% CI: 6.49-15.10%), reported by two studies; however, the comparison with non-exposed pregnant persons, available for one study, found non-statistically significant differences (adjusted OR 1.09; 95% CI 0.56-2.12). Animal studies showed consistent results with studies in pregnant persons. We found no safety concerns for currently administered COVID-19 vaccines during pregnancy. Additional experimental and real-world evidence could enhance vaccination coverage. Robust safety data for non-mRNA-based COVID-19 vaccines are still needed.